References
- Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson heart study cohorts. Am J Hum Genet. 2012;91:513–519.
- Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346(8969):211–214.
- Khouzam R, Naidu SS. Current status and future perspectives on alcohol septal ablation for hypertrophic cardiomyopathy. Curr Cardiol Rep. 2014;16(5):478.
- Gersh BJ, Maron BJ, Bonow RO, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2011;58(25):e212–60.
- Elliott PM, Anastasakis A, Borger MA, et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology. Eur Heart J. 2014;35(39):2733–2779.
- Agarwal S, Tuzcu EM, Desai MY, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55:823–834.
- Steggerda RC, Damman K, Balt JC, et al. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. JACC Cardiovasc Interv. 2014;7(11):1227–1234.
- Leonardi RA, Kransdorf EP, Simel DL, et al. Meta-analysis of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3:97–104.
- Liebregts M, Pa V, Bk M, et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Failure. 2015;3(11):896.
- Nagueh SF, Groves BM, Schwartz L, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: a multi-center North American registry. J Am Coll Cardiol. 2011;58(22):2322–2328.
- Sorajja P, Ommen SR, Holmes DR Jr, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126(20):2374–2380.
- Schafer U, Kreidel F, Frerker C. MitraClipimplantation as a new treatment strategy against systolic anterior motion-induced outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Heart Lung Circ. 2014;23(5):e131–5.
- Monteiro PF, Ommen SR, Gersh BJ, et al. Effects of surgical septal myectomy on left ventricular wall thickness and diastolic filling. Am J Cardiol. 2007;100(12):1776–1778.
- Jassal DS, Neilan TG, Fifer MA, et al. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J. 2006;27(15):1805–1810.
- Olivotto I, Ommen SR, Maron MS, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol. 2007;50(9):831–834.
- Kim LK, Swaminathan RV, Looser P, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. JAMA Cardiol. 2016;1(3):324–332.
- Ommen SR, Nishimura RA. Hypertrophic cardiomyopathy – one case per year?: a clarion call to do what is right. JAMA Cardiol. 2016;1(3):333–334.